SEQUENCE LISTING

<110> FERRING B.V.

<120> NOVEL USE

<130> 052209-0113

<150> US 60/538,512
<151> 2004-01-26

<160> 43

<170> PatentIn version 3.2

<210> 1
<211> 34
<212> PRT
<213> Homo sapiens

<400> 1
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1   5   10   15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20   25   30

Asn Phe

<210> 2
<211> 34
<212> PRT
<213> Bos taurus

<400> 2
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1   5   10   15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20   25   30

Asn Phe

<210> 3
<211> 34
<212> PRT
<213> Homo sapiens

```
<400> 3
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1               5               10              15


Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
            20              25              30


Thr Ala



<210> 4
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (23)..(23)
<223> 2-Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 4
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Xaa Lys His Leu Ser
1               5               10              15


Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20              25              30


Asn Tyr
```

```
<210> 5
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1               5                   10                  15


Ser Met Glu Arg Val Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His
            20                  25                  30


Asn Phe
```

```
<210> 6
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 6
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1               5                   10                  15


Ser Met Glu Arg Val Glu Trp Leu Glu Lys Lys Leu Glu Lys Val His
            20                  25                  30


Asn Phe
```

```
<210> 7
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide
```

<220>
<223> see specification as filed for preferred embodiments

<400> 7
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1   5   10   15

Ser Met Glu Arg Val Glu Leu Leu Arg Lys Leu Leu Gln Asp Leu His
            20   25   30

Asn Phe

<210> 8
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (26)..(26)
<223> Aib

<220>
<223> see specification as filed for preferred embodiments

<400> 8
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1   5   10   15

Asp Leu Arg Arg Arg Phe Phe Leu His Xaa Leu Ile Ala Glu Ile His
            20   25   30

Thr Ala

<210> 9
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES

<222> (32)..(32)
<223> Thi

<220>
<223> see specification as filed for preferred embodiments

<400> 9
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1   5   10   15

Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Xaa
            20   25   30

Thr Ala

<210> 10
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 10
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1   5   10   15

Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Leu Leu His
            20   25   30

Thr Ala

<210> 11
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 11
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1   5   10   15

```
Asp Leu Arg Arg Arg Phe Leu Leu His His Leu Leu Ala Glu Leu His
            20                  25                  30


Thr Ala



<210> 12
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 12
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1               5                   10                  15


Asp Leu Arg Arg Arg Glu Phe Leu Glu Lys Leu Ile Glu Lys Ile His
            20                  25                  30


Thr Ala



<210> 13
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal
```

<220>
<223> see specification as filed for preferred embodiments

<400> 13
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1   5   10   15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20   25   30

Asn Tyr

<210> 14
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 14
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1   5   10   15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20   25   30

Asn Tyr

```
<210> 15
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 15
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Tyr



<210> 16
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
```

```
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 16
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1               5               10              15


Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20              25              30


Asn Tyr



<210> 17
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu
```

```
<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 17
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Tyr



<210> 18
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (16)..(16)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 18
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Xaa
1               5                   10                  15


Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30
```

Asn Phe


```
<210> 19
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (20)..(20)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 19
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Glu Xaa Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe


<210> 20
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala


<220>
<221> MOD_RES
```

```
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 20
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5               10                  15


Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20              25                  30


Asn Phe



<210> 21
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 21
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5               10                  15


Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20              25                  30


Asn Phe



<210> 22
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide
```

```
<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 22
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 23
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 23
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30
```

```
Asn Phe


<210> 24
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 24
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe


<210> 25
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments
```

```
<400> 25
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20              25                  30


Asn Phe



<210> 26
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 26
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
        20              25                  30


Asn Phe



<210> 27
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide
```

```
<220>
<221> MOD_RES
<222> (18)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 27
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 28
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 28
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30
```

Asn Phe

<210> 29
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 29
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1   5   10   15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20   25   30

Asn Phe

<210> 30
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

```
<220>
<223> see specification as filed for preferred embodiments

<400> 30
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 31
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 31
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 32
<211> 34
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 32
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1                5                10                15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                25                30


Asn Phe



<210> 33
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle


<220>
<221> MOD_RES
```

```
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 33
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 34
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 34
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
            20                  25                  30


His Asn Phe
            35
```

```
<210> 35
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 35
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 36
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(18)
<223> beta-Ala
```

```
<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 36
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 37
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 37
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30
```

Asn Phe


```
<210> 38
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 38
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5               10              15


Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20              25              30
```

Asn Phe


```
<210> 39
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu
```

```
<220>
<223> see specification as filed for preferred embodiments

<400> 39
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 40
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 40
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe
```

```
<210> 41
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 41
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1               5                   10                  15


Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe



<210> 42
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle


<220>
<221> MOD_RES
```

```
<222> (12)..(12)
<223> Aib

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (23)..(23)
<223> 2-Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 42
Ser Val Ser Glu Ile Gln Leu Xaa His Asn Leu Xaa Lys His Leu Asn
1               5                   10                  15


Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Tyr
```

```
<210> 43
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide


<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib

<220>
<223> see specification as filed for preferred embodiments

<400> 43
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Xaa Lys His Leu Asn
1               5                   10                  15


Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
            20                  25                  30


Asn Phe
```